X-ZELL is a cutting-edge med-tech brand founded by Dr. Sebastian C. P.

Bhakdi, an experienced physician with a background in paediatrics and emergency health. Dr. Bhakdi's passion for entrepreneurship led him to establish Thailand's first Silicon Valley-backed med-tech company in 2010.

X-ZELL has since made remarkable strides in the industry. They developed a revolutionary cell separation method for tropical disease diagnostics and launched the university's inaugural spin-off company. By 2018, X-ZELL had collaborated with the Diagnostics Development (DxD) Hub in Singapore to accelerate the commercialization of groundbreaking medical technology.

With the opening of their global head office in Singapore in 2019, X-ZELL focused on optimizing and digitizing cytopathological testing, with blood as a primary diagnostic data source. Renowned for their innovation, X-ZELL garnered accolades, including being ranked the second-most innovative healthcare start-up in the world in 2020 and winning the MedTech Innovator APAC award. In 2021, X-ZELL expanded its presence, establishing its first European office in Germany.

They also embarked on a significant trial for the early detection of clinically significant prostate cancer using blood samples. To further enhance cytology analysis, X-ZELL collaborated with a leading German cytopathology center in 2022. With their dynamic team, including Chief Operations Officer Johannes Hille, Managing Director Sebastian Grote, and Quality & Regulatory Affairs expert Claire Fives, X-ZELL is at the forefront of next-generation cytology